Premium
The effects of amrinone on platelet count, survival and function in patients with congestive cardiac failure.
Author(s) -
Wilmshurst PT,
AlHasani SF,
Semple MJ,
Hamblin AS,
Kioy PG,
Lucas GF,
Savidge GF,
WebbPeploe MM
Publication year - 1984
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1984.tb02347.x
Subject(s) - medicine , platelet , amrinone , heart failure , refractory (planetary science) , cardiology , cardiac function curve , physics , astrobiology
In a prospective trial, the immediate and long‐term haematological effects of amrinone were studied in sixteen patients with refractory cardiac failure. The platelet count was significantly and variably reduced in all patients and the reduction was related to log plasma amrinone concentration. Platelet survival was significantly reduced in those cases studied. No evidence of disseminated intravascular coagulation or intravascular platelet deposition was observed and the reduced platelet survival was not considered to be the result of an immunological process. Evidence of a marrow response to the reduced platelet count and survival was seen. Although no haemorrhagic symptoms were observed in the patients, the haematological side‐effects were considered to be of such severity as to limit the use of this drug in clinical practice.